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Abstract
Background The laparoscopic vertical sleeve gastrectomy
(LSG) is derived from the biliopancreatic diversion with
duodenal switch operation (Marceau et al., Obes Surg 3:29–
35, 1993; Hess and Hess, Obes Surg 8:267–82, 1998; Chu
et al., Surg Endosc 16:S069, 2002). Later, LSG was
advocated as the first step of a two-stage procedure for
super-obese patients (Regan et al., Obes Surg 13:861–4,
2003; Cottam et al., Surg Endosc 20:859–63, 2006).
However, recent support is mounting that continues to
establish LSG as the definitive procedure for surgical
treatment of morbid obesity. We will report our experience
with the LSG as a primary bariatric procedure and evaluate
if this operation is suitable as a stand-alone procedure.
Methods The study is a nonrandomized retrospective
analysis of 204 patients from a single surgeon operated
between July 2006 and April 2010. The study comprises of
155 women and 49 men with a mean age of 45 years
(range, 19–70 years), a mean preoperative weight of
126.6 kg, and body mass index (BMI) of 45.7 kg/m
2.
Results The mean percent excess weight loss (%EWL) was
49.9% (n=159), 64.2% (n=138), 67.9% (n=77), 62.4% (n=
34), and 62.2% (n=9) at 3, 6, 12, 24, and 36 months,
respectively. For patients with BMI ≤43.0, the mean
postoperative %EWL was 58.9% (n=72), 74.1% (n=67),
75.8% (n=39), 72.1% (n=17), and 78.7% (n= 5 )a t3 ,6 ,1 2 ,
24, and 36 months, respectively. Operative complications
include leak (0.0%), abscess (0.5%), hemorrhage (1.0%),
sleeve stricture (1.0%), and severe gastroesphogeal reflux
disease with need to convert to laparoscopic Roux-en-Y
gastric bypass (0.5%).
Conclusions LSG yields excellent outcomes with low
complication rates for morbidly obese patients. We advo-
cate LSG as a safe and effective stand-alone procedure,
especially with the lower BMI population (BMI 35.0–
43.0 kg/m
2).
Keywords Bariatric surgery.Morbid obesity.Sleeve
gastrectomy.Gastric bypass.Lower BMI population
Introduction
The laparoscopic vertical sleeve gastrectomy (LSG) is
derived from the biliopancreatic diversion with duodenal
switch operation (BPD-DS) [1–3]. Sleeve gastrectomy
functioned as the restrictive component of the procedure.
Later, LSG was advocated as the first step of a two-staged
procedure for high-risk patients, with the intention of
reducing co-morbidities and operative risk, and to be
followed by either BPD-DS or laparoscopic Roux-en-Y
gastric bypass (LRYGB) [4, 5]. However, often, satisfacto-
ry weight loss was achieved after LSG, and second-stage
procedures were found to be unnecessary [6, 7]. Because of
the success of LSG in the first stage, it is gaining
momentum as an isolated bariatric procedure [8–10].
The success of the sleeve can be attributed to two
main factors. First, a high-pressure system is conceived
from a narrow lumen with the pylorus intact, which
results in optimal restriction and improved satiety [11].
Essentially, LSG is a derivative of the Magenstrasse and
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distally [12, 13]. Second, appetite suppression is achieved
by removing the gastric fundus, the ghrelin-producing
portion of the stomach. Numerous studies indicate that
sharp declines in fasting and postprandial levels of this
orexigenic hormone following LSG cause a long-term
reduction of hunger feeling, which significantly reduces
intake [14–18].
The aim of this retrospective, nonrandomized study is to
report our experience with LSG as a primary bariatric
procedure and determine if this operation is suitable for the
lower body mass index (BMI) population (35.0–43.0 kg/m
2).
Materials and Methods
Between July 2006 and April 2010, 204 patients underwent
LSG performed by a single surgeon. The study group
consisted of 155 women and 49 men with a mean age of
45 years (range, 19–70 years), a mean preoperative weight
of 126.6 kg, and mean BMI of 45.7 kg/m
2. The mean OR
time was 92±32 min, and mean length of stay was 2.3 days.
A nonrandomized retrospective analysis was done.
Surgical Technique
The operation was performed under general anesthesia. A
Verres needle is inserted in the left upper quadrant with
insufflations of the abdominal cavity to a pressure of
15 mmHg. Six laparoscopic ports are inserted, three 5-mm
and three 12-mm Endopath® Xcel™ Bladeless trocars
(Ethicon Endo-Surgery, Inc.). The short gastric vessels are
taken down along the greater curvature of the stomach with
a Harmonic® scalpel (Ethicon Endo-Surgery, Inc.) approx-
imately 3 cm from the pylorus, extending cephalad, taking
the adhesions down around the fundus of the stomach.
Once freed, a 34-Fr Edlich tube is inserted by anesthesia.
This is guided to hug the lesser curvature. Once the Edlich
tube is placed, sequential firings of the Echelon® 60™
Endopath stapler (Ethicon Endo-Surgery, Inc.) with the
green cartridge, as well as the Seamguard® (W. L. Gore &
Associates, Inc.) reinforcement, are used to transect the
lateral stomach to create a vertical gastrectomy. Before each
firing, adequate tension is ensured to avoid excess tissue
under the sleeve that is measured against a 34-Fr bougie. A
small margin of gastric tissue is left at the angle of His.
Once the gastrectomy is complete, the endoscope is inserted
into the oral cavity, down the esophagus, and into the
vertical stomach. Air is insufflated, and irrigation is sprayed
upon the staple line to check for leaks. The staple line is
then reinforced with Tisseel® glue (Baxter International,
Inc.). The gastric remnant is removed through the left lower
quadrant port after placing fascial stitches. A Blake® drain
is placed and brought out through the right upper quadrant
port incision.
Postoperative Care
We have a comprehensive multidisciplinary Center of
Excellence led by a single surgeon. The surgeon operates
with a physician assistant as first assist and a consistent
core of surgical techs. Follow-up appointments with
complete lab assessments are done routinely at 1 week,
2 weeks, 5 weeks, 3 months, 6 months, 9 months, 1 year,
18 months, and 2 years post-operation. Patients are then
seen annually or more frequently if desired. Nutrition
classes led by a registered dietitian occur both before and
after surgery through 1 year post-operation. A psycholog-
ical assessment is completed on each patient prior to
surgery with multiple social worker led support groups
each month.
A UGI is completed on post-operation day (POD) 1 to
evaluate the staple line before the advancement of diet. Diet
then follows that of RYGB starting with clear liquids on
POD 1. On POD 3, liquid protein begins, which continue
for 3 weeks, followed by soft protein diet for 5 weeks, and
eventually solid protein diet by 8 weeks as tolerated. A
proton pump inhibitor is given 3–6 months postoperatively
along with MVI, B12, and calcium. Chewable forms of
vitamins are encouraged until 3 months post-op. Fig. 1 Comparison of %EWL between LSG and LRYGB
Fig. 2 Comparison of %EWL between LSG and LRYGB for BMI
35.0–43.0 kg/m
2
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The mean postoperative percent excess weight loss (%
EWL) was 49.9% (n=159), 64.2% (n=138), 67.9% (n=77),
62.4% (n=34), and 62.2% (n=9) at 3, 6, 12, 24, and
36 months, respectively (Fig. 1). Upon further evaluation,
those LSG patients with BMI 35.0–43.0 kg/m
2 had similar
mean postoperative %EWL to the established averages of
LRYGB [19]. For patients with BMI 35.0–43.0 kg/m
2, the
mean postoperative %EWL was 58.9% (n=72), 74.1% (n=
67), 75.8% (n=39), 72.1% (n=17), and 78.7% (n=5) at 3,
6, 12, 24, and 36 months, respectively (Fig. 2).
LSG has a significant effect on the resolution or
improvement of comorbidities (Table 1). The rates for early
complications were 0.0% for leaks, 0.5% for abscess, 1.0%
for hemorrhage, and 1.0% for sleeve stricture. The
complication rate for severe gastroesphogeal reflux disease
(GERD) with need to convert to laparoscopic Roux-en-Y
gastric bypass is 0.5%.
Discussion
With data collected from 204 patients of a single surgeon,
we present one of the largest series of LSG intended as a
primary bariatric procedure in morbid obesity. Limitations
of our study are that it is nonrandom and retrospective.
Because different techniques for surgery exist across the
bariatric discipline, standardization is difficult. In our
Center of Excellence, we have standardized the LSG
technique with respect to surgical procedure, such as
narrowness of the gastric sleeve and abdominal access, as
well as patient education and support. Regardless of the
technique, maximizing patient education and support is
critical.
With our standardized technique, it is possible to
compare to the gold standard, LRYGB. Although our
center's LRYGB data is unpublished, we can compare the
results of LSG to LRYGB because these patients follow the
same pre- and post-operation multidisciplinary programs,
led by the same surgeon and bariatric team (Table 2; Fig. 1
and 2). Of note, our 12 months mean %EWL for LRYGB
of 72.4% is comparable to meta-analysis reports of 61.6%
[19].
When compared to LRYGB, benefits include no dump-
ing, a decreased occurrence of vitamin deficiencies, and no
interference with medication absorption. LSG is a viable
procedure for those patients with extensive adhesions,
inflammatory bowel syndrome, and long-term need for
nonsteroidal anti-inflammatory drugs [20, 21]. Complica-
tion rates are lower with LSG with no risk of internal hernia
or anastomotic issues such as stricture or ulcer [22]. In
addition, LSG affords convertibility to a second procedure
if suboptimal weight loss is achieved.
LSG is often approved by insurance providers for
BMI >50.0 kg/m
2, exclusively for super-obese patients as
the first step of a staged procedure. However, our results
indicate that LSG is an effective primary procedure especially
for the lower BMI population (35.0–43.0 kg/m
2). This
population often looks to laparoscopic adjustable gastric
band (LAGB) because they have less weight to lose, and the
procedure is less invasive. However, the LAGB—for which
insurance companies approve—introduces a foreign body,
requires adjustments, results in lower %EWL, and does not
decrease plasma ghrelin levels [15].
Comorbidity Number of patients Cases resolved and improved Percent
Hypertension 119 81 resolved, 35 improved 97.5
Diabetes 58 41 resolved, 16 improved 98.3
Hyperlipidemia 98 47 resolved, 48 improved 96.9
Depression 103 41 resolved, 61 improved 99.0
Obstructive sleep apnea 73 53 resolved, 18 improved 97.3
GERD 113 43 resolved, 69 improved 99.1
Arthritis 72 37 resolved, 34 improved 98.1
Chronic joint pain 44 26 resolved, 18 improved 100.0
Stress incontinence 44 41 resolved, 3 improved 100.0
Asthma 34 21 resolved, 13 improved 100.0
Table 1 Comorbidities
Resolved or Improved Post-
operation LSG
Table 2 Comparison of LSG to LRYGB
LSG LRYGB
N 204 1,912
Age at surgery (years) 45.0 49.6
OR time 92±32 min 105±29 min
Pre-op Wt (kg) 126.6 136.6
BMI (kg/m
2) 45.7 49.6
LOS (days) 2.3 2.2
%EWL at 12 months 67.9% (n=77) 72.4% (n=1,138)
1170 OBES SURG (2011) 21:1168–1171Conclusion
LSG yields excellent outcomes with low complication rates
for morbidly obese patients. It has many significant
advantages over other surgical bariatric treatments. We
advocate the LSG as a safe and effective stand-alone
procedure, especially with the lower BMI population (BMI
35.0–43.0 kg/m
2).
Conflicts of interest The authors declare that they have no conflicts
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Marceau P, Biron S, Bourque RA, et al. Biliopancreatic diversion
with a new type of gastrectomy. Obes Surg. 1993;3:29–35.
2. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal
switch. Obes Surg. 1998;8(3):267–82.
3. Chu CA, Gagner M, Quinn T, et al. Two-stage laparoscopic
biliopancreatic diversion with duodenal switch: an alternative
approach to super-super morbid obesity (abstract). Surg Endosc.
2002;16:S069.
4. Regan JP, Inabnet WB, Gagner M, et al. Early experience with
two-staged laparoscopic Roux-en-Y gastric bypass as an alterna-
tive in the super-super obese patient. Obes Surg. 2003;13:861–4.
5. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve
gastrectomy as an initial weight-loss procedure for high-risk
patients with morbid obesity. Surg Endosc. 2006;20:859–63.
6. Mongol P, Chosidow D, Marmuse JP. Laparoscopic sleeve
gastrectomy as an initial bariatric operation for high-risk patients:
initial results in 10 patients. Obes Surg. 2005;15:1030–3.
7. Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for
morbid obesity in 216 patients: report of two-year results. Surg
Endosc. 2007;21:1810.
8. Baltasar A, Serra C, Perez N, et al. Laparoscopic sleeve
gastrectomy: a multi-purpose bariatric operation. Obes Surg.
2005;15(8):1124–8.
9. Han MS, Kim WW, Oh JH. Results of laparoscopic sleeve
gastrectomy (LSG) at 1 year in morbidly obese Korean patients.
Obes Surg. 2005;15:1469–75.
10. Franz FX, Langer F, Shakeri-Manesch S, et al. Laparoscopic sleeve
gastrectomy as an isolated bariatric procedure: intermediate-term
results from a large series in three Austrian centers. Obes Surg.
2008;18:814–8.
11. Weiner RA, Weiner S, Pomhoff I, et al. Laparoscopic sleeve
gastrectomy—influence of sleeve size and resected gastric
volume. Obes Surg. 2007;17:1297–305.
12. Carmichael AR, Johnston D, Barker MC, et al. Gastric emptying
after a new, more physiological anti-obesity operation: the Magen-
strasse and Mill procedure. Eur J Nucl Med. 2001;28:1379–83.
13. Johnston D, Dachtler J, Sue-Ling HM, et al. The Magenstrasse
and Mill operation for morbid obesity. Obes Surg. 2003;13:10–6.
14. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source
of circulating ghrelin, and feeding state determines plasma
ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol
Metab. 2001;86:4753–8.
15. Langer FB, Reza Hoda MA, Bohdjalian A, et al. Sleeve
gastrectomy and gastric banding: effects on plasma ghrelin levels.
Obes Surg. 2005;15:1024–9.
16. Cummings DE. Ghrelin and the short- and long-term regulation of
appetite and body weight. Physiol Behav. 2006;89:71–84.
17. Rubino F, Gagner M. Weight loss and plasma ghrelin levels. N
Engl J Med. 2002;347:1379–81.
18. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss,
appetite suppression, and changes in fasting and postprandial
ghrelin and peptide-yy levels after Roux-en-Y gastric bypass and
sleeve gastrectomy. Ann Surg. 2008;247:401–7.
19. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a
systematic review and meta-analysis. JAMA. 2004;292:1724–
36.
20. Tucker ON, Szomstein S, Rosenthal RJ. Indications for sleeve
gastrectomy as a primary procedure for weight loss in the
morbidly obese. J Gastrointest Surg. 2008;12:662–7.
21. Roa PE, Kaidar-Person O, Pinto D, et al. Laparoscopic sleeve
gastrectomy as treatment for morbid obesity: technique and short-
term outcome. Obes Surg. 2006;16:1323–6.
22. Lakdawala MA, Bhasker A, Mulchandani D, et al. Comparison
between the results of laparoscopic sleeve gastrectomy and
laparoscopic Roux-en-Y gastric bypass in the Indian population:
a retrospective 1 year study. Obes Surg. 2009;20:1–6.
OBES SURG (2011) 21:1168–1171 1171